The company on Tuesday said that a study of oral nalbuphine showed clinical doses of the drug demonstrated a statistically significant lower "drug liking" compared with intravenous butorphanol.

Shares of Trevi Therapeutics (NASDAQ:TRVI) tumbled 23% Tuesday post-market after the company reported topline results from a ...

NDAQ:TRVI) Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine ...

The agency tallied 577 infections of pertussis nationwide for the week ending Nov. 23, around 33% higher than last week's ...

The number of walking pneumonia cases seen in Ontario this year is triple the amount of what was reported in 2019, before the ...

Stephen, who was diagnosed with cancer at 29, has shared his story in a video that has since gone viral as he discussed the ...

In Brazil’s Minas Gerais – the biggest coffee-growing state in the world’s No. 1 bean producer – farmers and exporters ...

In 2024, Yellowstone County has so far confirmed 11 cases, compared to one case between 2020-2023. Six of those cases were ...

Health authorities are urging West Australians to keep their whooping cough immunisations up to date after the State recorded ...

A well-used temporary clinic will soon make its return to Chatham-Kent Health Alliance. The hospital, in partnership with ...